The undersigned, Gergely Tölgyesi PhD, Head of of Omixon Biocomputing Ltd, Budapest, Hungary, hereby declares that the following preparations -
Fragmentation Buffer (B) R21/R22
-
Enhancer 1 E01
-
Enhancer 2 E02
-
HLA-A Primer Mix P013/P012
-
HLA-B Primer Mix P023/P022
-
HLA-C Primer Mix P033/P032
-
HLA-DRB 1 Primer Mix P042/043
-
HLA-DRB1/DRB3 Primer Mix P42.1/P43.1
-
HLA-DRB4 Primer Mix P102/P103
-
HLADRB5 Primer Mix P112/113
-
HLA-DQB1 set 1 Primer Mix P053/P052
-
HLA- DQB1 set 2 Primer Mix P063/P062
-
HLA –DQB 1 set 3 Primer mix P122/P123
-
HLA-DPB1 Primer Mix P072/P073
-
HLA-DPA1 Primer Mix P132/P133
-
HLA-DQA1 Primer Mix P083/P082
-
Adaptor Plate A (i1-96) N1
Issue Date: 2018.01.15 Version: 2 Status: Current
-
Adaptor Plate B (i97-192) N2
-
Adaptor Plate A1 (i1-24) N4
-
Adaptor Plate A2 (i25-48) N7
-
Adaptor Plate A3 (i49-72) N8
-
Adaptor Plate A4 (i72-96) N9
sold by Omixon, do not contain dangerous substances, as defined in European Regulation (EC) No 1272/2008 on classification, labeling and packaging of substances and mixtures, at concentrations requiring the distribution of Safety Data Sheets as specified in the REACH regulation 1907/2006. Therefore, Safety Data Sheets for these products have not been created.
2018/01/10
(Signature) Name: Gergely Tölgyesi, PhD Function: Head of Assay R & D